Gut Bacteria Linked to Liver Disease Severity
A study of 93 bariatric surgery patients links gut microbes and metabolites to liver gene activity in fatty liver disease.
Updated on Nov. 6, 2026 in Life Sciences
Researchers examined liver gene activity, gut microbiome and metabolite profiles in 93 patients undergoing bariatric surgery who had metabolic dysfunction-associated steatotic liver disease (MASLD). Certain bacterial species and metabolites were associated with liver gene expression patterns tied to disease severity.
Why it matters
MASLD is a common liver condition, and the findings point to gut bacteria and their metabolites as possible contributors to how the disease progresses. Because the associations did not remain significant after adjusting for known covariates, the link remains an open question for further research.
The study used metagenomics to profile gut bacteria and mass measurements of serum and fecal metabolites across 93 bariatric surgery patients. Once adjusted for known confounding factors, the associations between liver gene expression and bacterial taxa or metabolites were no longer statistically significant.
The details
Patients provided blood and fecal samples before surgery, and a liver biopsy was taken to assess histology and the hepatic transcriptome. Patients with metabolic dysfunction-associated steatohepatitis showed higher expression of genes tied to immune response, inflammation, cancer and apoptosis, while those with severe fibrosis showed higher extracellular matrix gene expression and more Collinsella stercoris.
Timeline
Blood and fecal samples were collected from patients prior to their bariatric surgery.
The article was published as accepted early-access research on November 6, 2026.
The Big Picture
The study uses the MASLD classification, which replaced the earlier term nonalcoholic fatty liver disease and reflects a shift toward metabolic risk factors. Its findings add to a growing body of work exploring whether gut microbes influence liver disease progression within that framework.
The findings may eventually inform how clinicians think about gut bacteria as a factor in fatty liver disease, though the study does not establish any treatment. For now the results remain at the research stage and do not change current care for patients.
The takeaway
Gut microbes may be one piece of the puzzle in liver disease, but researchers still need to determine whether they cause changes or simply accompany them. Readers interested in liver health should focus on the established factors of diet, weight and metabolic health while the science develops.
Further reading
Explore more on the Life Sciences section for related research on the biology of the body and its microbes.
Source note: This article includes information reported by Nature.
